40155-54-2

Basic information

• Product Name: Benzenebutanoic acid, 4-broMo-.alpha.,.gaMMa.-dioxo-, ethyl este
• Synonyms: Benzenebutanoic acid, 4-broMo-.alpha.,.gaMMa.-dioxo-, ethyl este;Benzenebutanoic acid, 4-broMo-.alpha.,.gaMMa.-dioxo-, ethyl ester;Ethyl 4-broMo-a,g-dioxo-benzenebutanoate;4-(4-bromophenyl)-2,4-dioxobutyric acid ethyl ester
• CAS NO: 40155-54-2
• Molecular Formula: C₁₂H₁₁BrO₄
• Molecular Weight: 299.11734
• Mol File: 40155-54-2.mol
• Article Data: 26

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenebutanoic acid, 4-broMo-.alpha.,.gaMMa.-dioxo-, ethyl este(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenebutanoic acid, 4-broMo-.alpha.,.gaMMa.-dioxo-, ethyl este(40155-54-2)
• EPA Substance Registry System: Benzenebutanoic acid, 4-broMo-.alpha.,.gaMMa.-dioxo-, ethyl este(40155-54-2)

Safety Data

• Hazardous Substances Data: 40155-54-2(Hazardous Substances Data)

Usage

General Description

Benzenebutanoic acid, 4-bromo-α,γ-dioxo-, ethyl ester is a chemical compound that is commonly used in organic synthesis. It is an ethyl ester derivative of 4-bromo-α,γ-dioxo-benzenebutanoic acid, which is an important intermediate for the synthesis of various pharmaceutical compounds and agrochemicals. Benzenebutanoic acid, 4-broMo-.alpha.,.gaMMa.-dioxo-, ethyl este is often used as a building block in the synthesis of more complex molecules and is known for its reactivity and ability to participate in a wide range of chemical reactions. Its versatility makes it a valuable tool for researchers and chemists working in the fields of drug discovery and chemical synthesis.

Upstream product

• 1064075-16-6 C₁₂H₁₂BrNO₃ 
• 140-88-5 ethyl acrylate 
• 1122-91-4 4-bromo-benzaldehyde 
• 73900-14-8 1-bromo-4-(diazomethyl)benzene 
• 25062-46-8 4-bromobenzaldehyde oxime 
• 19350-68-6 p-bromobenzaldehyde tosylhydrazone 
• 99-90-1 para-bromoacetophenone 
• 122-51-0 orthoformic acid triethyl ester 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 1197207-80-9 ethyl 3-(4-bromobenzoyl)-4-ethoxy-2-oxobut-3-enoate 
• 618070-50-1 1-methyl-3-(4-bromophenyl)-1H-pyrazole-5-carboxylic acid ethyl ester 
• 852815-31-7 ethyl 5-(4-bromophenyl)-1-methyl-1H-pyrazole-3-carboxylate 
• 128918-27-4 3-Amino-6-(4-bromo-phenyl)-2-diethylcarbamoyl-thieno[2,3-b]pyridine-4-carboxylic acid ethyl ester 
• 33277-15-5 ethyl 5-(4-bromo-phenyl)-isoxazole-3-carboxylate 
• 1240314-18-4 C₁₅H₁₉BrO₄Si 

Relevant articles and documents

[2 + 2 + 1] Cycloaddition ofN-tosylhydrazones,tert-butyl nitrite and alkenes: a general and practical access to isoxazolines

N-Tosylhydrazones have proven to be versatile synthons over the past several decades. However, to our knowledge, the construction of isoxazolines based onN-tosylhydrazones has not been examined. Herein, we report the first demonstrations of [2 + 2 + 1] cycloaddition reactions that allow the facile synthesis of isoxazolines, employingN-tosylhydrazones,tert-butyl nitrite (TBN) and alkenes as reactants. This process represents a new type of cycloaddition reaction with a distinct mechanism that does not involve the participation of nitrile oxides. This approach is both general and practical and exhibits a wide substrate scope, nearly universal functional group compatibility, tolerance of moisture and air, the potential for functionalization of complex bioactive molecules and is readily scaled up. Both control experiments and theoretical calculations indicate that this transformation proceedsviathein situgeneration of a nitronate from the coupling ofN-tosylhydrazone and TBN, followed by cycloaddition with an alkene and subsequent elimination of atert-butyloxy group to give the desired isoxazoline.

Novel N-benzylpiperidine derivatives of 5-arylisoxazole-3-carboxamides as anti-Alzheimer's agents

The complex pathophysiology of Alzheimer's disease (AD) has prompted researchers to develop multitarget-directed molecules to find an effective therapy against the disease. In this context, a novel series of N-(1-benzylpiperidin-4-yl)-5-arylisoxazole-3-ca

Design and synthesis of novel 5-arylisoxazole-1,3,4-thiadiazole hybrids as α-glucosidase inhibitors

Background: α-Glucosidase inhibitors have occupied a significant position in the treatment of type 2 diabetes. In this respect, the development of novel and efficient non-sugar-based inhibitors is in high demand. Objective: Design and synthesis of new 5-arylisoxazole-1,3,4-thiadiazole hybrids possessing α-glucosidase inhibitory activity were developed. Methods: Different derivatives were synthesized by the reaction of various 5-arylisoxazole-3-carboxylic acids and ethyl 2-((5-amino-1,3,4-thiadiazol-2-yl)thio)acetate. Finally, they were evalu-ated for their α-glucosidase inhibitory activity. Results: It was found that ethyl 2-((5-(5-(2-chlorophenyl)isoxazole-3-carboxamido)-1,3,4-thiadiazol-2-yl)thio)acetate (5j) was the most potent compound (IC50 = 180.1 μM) compared with acarbose as the reference drug (IC50 = 750.0 μM). Also, the kinetic study of 5j revealed a competitive inhibition and docking study results indicated desired interactions of that compound with amino acid residues located close to the active site of α-glucosidase. Conclusion: Good α-glucosidase inhibitory activity obtained by the title compounds introduced them as an efficient scaffold, which merits to be considered in anti-diabetic drug discovery developments.